Substituted 4-phenyl-2-aminoimidazoles and 4-phenyl-4,5-dihydro-2- aminoimidazoles as voltage-gated sodium channel modulators

European Journal of Medicinal Chemistry

Volumn 74, Issue , 2014, Pages 23-30

  Zidar, Nace ^a   Jakopin, Žiga ^a   Madge, David J ^b   Chan, Fiona ^b   Tytgat, Jan ^c   Peigneur, Steve ^c   Dolenc, Marija Sollner ^a   Tomašić, Tihomir ^a   Ilaš, Janez ^a   Mašič, Lucija Peterlin ^a   Kikelj, Danijel ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Xention Limited   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

4 Phenyl 2 aminoimidazole; Clathrodin; Marine alkaloid; NaV channel modulator; Pyrrole 2 aminoimidazole; Voltage gated sodium channel

Indexed keywords

2 (3 NITROPHENYL) 1H IMIDAZO[1,2 A]PYRIMIDIN 4 IUM BROMIDE; 4 (3 NITROPHENYL) 1H IMIDAZOL 2 AMINE; 4 [3 (1H PYRROLE 2 CARBOXAMIDO)PHENYL] 2 AMINO 1H IMIDAZOL 3 IUM CHLORIDE; 4 [4 (1H PYRROLE 2 CARBOXAMIDO)PHENYL] 2 AMINO 1H IMIDAZOL 3 IUM CHLORIDE; 4 PHENYL 2 AMINOIMIDAZOLE; 4 PHENYL 4,5 DIHYDRO 2 AMINOIMIDAZOLE; IMIDAZOLE DERIVATIVE; LIDOCAINE; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.7; TERT BUTYL 2 AMINO 4 (3 AMINOPHENYL) 1H IMIDAZOLE 1 CARBOXYLATE; TERT BUTYL 2 AMINO 4 (3 NITROPHENYL) 1H IMIDAZOLE 1 CARBOXYLATE; TERT BUTYL 4 [3 (1H PYRROLE 2 CARBOXAMIDO)PHENYL] 2 AMINO 1H IMIDAZOLE 1 CARBOXYLATE; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; AUTOMATED PATCH CLAMP; DRUG DESIGN; DRUG SYNTHESIS; HEART ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

4-PHENYL-2-AMINOIMIDAZOLE; CLATHRODIN; MARINE ALKALOID; NA(V) CHANNEL MODULATOR; PYRROLE-2-AMINOIMIDAZOLE; VOLTAGE-GATED SODIUM CHANNEL;

IMIDAZOLES; INHIBITORY CONCENTRATION 50; ION CHANNEL GATING; MAGNETIC RESONANCE SPECTROSCOPY; SODIUM CHANNELS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, INFRARED;

EID: 84892682123     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.12.034     Document Type: Article

References (37)

1. J. Payandeh, T.M.G. El-Din, T. Scheuer, N. Zheng, and W.A. Catterall Crystal structure of a voltage-gated sodium channel in two potentially inactivated states Nature 486 2012 135 139
2. X. Zhang, W.L. Ren, P. DeCaen, C.Y. Yan, X. Tao, L. Tang, J.J. Wang, K. Hasegawa, T. Kumasaka, J.H. He, J.W. Wang, D.E. Clapham, and N. Yan Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel Nature 486 2012 130 134
3. J. Payandeh, T. Scheuer, N. Zheng, and W.A. Catterall The crystal structure of a voltage-gated sodium channel Nature 475 2011 353 358
4. W.A. Catterall Ion channel voltage sensors: structure, function, and pathophysiology Neuron 67 2010 915 928
5. F.H. Yu, and W.A. Catterall Overview of the voltage-gated sodium channel family Genome Biol. 4 2003
6. C. Sato, Y. Ueno, K. Asai, K. Takahashi, M. Sato, A. Engel, and Y. Fujiyoshi The voltage-sensitive sodium channel is a bell-shaped molecule with several cavities Nature 409 2001 1047 1051
7. W.A. Catterall From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels Neuron 26 2000 13 25
8. V. Zuliani, M.K. Patel, M. Fantini, and M. Rivara Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential Curr. Top. Med. Chem. 9 2009 396 415
9. S. England, and M.J. de Groot Subtype-selective targeting of voltage-gated sodium channels Br. J. Pharmacol. 158 2009 1413 1425
10. I. Tarnawa, H. Bolcskei, and P. Kocsis Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases Recent Pat. CNS Drug Discov. 2 2007 57 78
11. J.N. Wood, and J. Boorman Voltage-gated sodium channel blockers; target validation and therapeutic potential Curr. Top. Med. Chem. 5 2005 529 537
12. v1.1 sodium channels cause epilepsy? Brain Res. Rev. 58 2008 149 159
13. C. Lossin, T.H. Rhodes, R.R. Desai, C.G. Vanoye, D. Wang, S. Carniciu, O. Devinsky, and A.L. George Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A J. Neurosci. 23 2003 11289 11295
14. K.M. Kahlig, T.H. Rhodes, M. Pusch, T. Freilinger, J.M. Pereira-Monteiro, M.D. Ferrari, A.M.J.M. van den Maagdenberg, M. Dichgans, and A.L. George Divergent sodium channel defects in familial hemiplegic migraine Proc. Natl. Acad. Sci. U. S. A. 105 2008 9799 9804
15. S.B. Hoyt, C. London, C. Abbadie, J.P. Felix, M.L. Garcia, N. Jochnowitz, B.V. Karanam, X.H. Li, K.A. Lyons, E. McGowan, B.T. Priest, M.M. Smith, V.A. Warren, B.S. Thomas-Fowlkes, G.J. Kaczorowski, and J.L. Duffy A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain Bioorg. Med. Chem. Lett. 23 2013 3640 3645
16. S.D. Dib-Hajj, A.M. Binshtok, T.R. Cummins, M.F. Jarvis, T. Samad, and K. Zimmermann Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment Brain Res. Rev. 60 2009 65 83
17. S.C. Cannon Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses Kidney Int. 57 2000 772 779
18. T. Zimmer, and R. Surber SCN5A channelopathies - an update on mutations and mechanisms Prog. Biophys. Mol. Biol. 98 2008 120 136
19. A. Wickenden, B. Priest, and G. Erdemli Ion channel drug discovery: challenges and future directions Future Med. Chem. 4 2012 661 679
20. J.J. Clare, S.N. Tate, M. Nobbs, and M.A. Romanos Voltage-gated sodium channels as therapeutic targets Drug. Discov. Today 5 2000 506 520
21. v1.7 antagonists Bioorg. Med. Chem. Lett. 22 2012 1055 1060
22. v1.7 antagonists Bioorg. Med. Chem. Lett. 22 2012 2052 2062
23. v1.7 antagonists: hit-to-lead identification and SAR Bioorg. Med. Chem. Lett. 22 2012 2033 2042
24. I. Macsari, L. Sandberg, Y. Besidski, Y. Gravenfors, T. Ginman, J. Bylund, T. Bueters, A.B. Eriksson, P.E. Lund, E. Venyike, and P.I. Arvidsson Phenyl isoxazole voltage-gated sodium channel blockers: structure and activity relationship Bioorg. Med. Chem. Lett. 21 2011 3871 3876
25. v1.7 with oral efficacy in the formalin model of persistent pain J. Med. Chem. 54 2011 4427 4445
26. H.L. Li, A. Galue, L. Meadows, and D.S. Ragsdale A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel Mol. Pharmacol. 55 1999 134 141
27. + channels in rat hippocampal neurones Br. J. Pharmacol. 121 1997 1231 1238
28. A. Al-Sabi, J. McArthur, V. Ostroumov, and R.J. French Marine toxins that target voltage-gated sodium channels Mar. Drugs 4 2006 157 192
29. T. Yasumoto The chemistry and biological function of natural marine toxins Chem. Rec. 1 2001 228 242
30. A.L.R. Rentas, R. Rosa, A.D. Rodriguez, and G.E. Demotta Effect of alkaloid toxins from tropical marine sponges on membrane sodium currents Toxicon 33 1995 491 497
31. A. Al-Mourabit, M.A. Zancanella, S. Tilvi, and D. Romo Biosynthesis, asymmetric synthesis, and pharmacology, including cellular targets, of the pyrrole-2-aminoimidazole marine alkaloids Nat. Prod. Rep. 28 2011 1229 1260
32. B. Forte, B. Malgesini, C. Piutti, F. Quartieri, A. Scolaro, and G. Papeo A submarine journey: the pyrrole-imidazole alkaloids Mar. Drugs 7 2009 705 753
33. T. Lindel, G. Breckle, M. Hochgurtel, C. Volk, A. Grube, and M. Kock Decomposition of oroidin in DMSO/TFA Tetrahedron Lett. 45 2004 8149 8152
34. C. Poverlein, G. Breckle, and T. Lindel Diels-Alder reactions of oroidin and model compounds Org. Lett. 8 2006 819 821
35. P.J. Dransfield, S.H. Wang, A. Dilley, and D. Romo Highly regioselective Diels-Alder reactions toward oroidin alkaloids: use of a tosylvinyl moiety as a nitrogen masking group with adjustable electronics Org. Lett. 7 2005 4065-4065
36. D.S. Ermolat'ev, and E.V. Van der Eycken A divergent synthesis of substituted 2-aminoimidazoles from 2-aminopyrimidines J. Org. Chem. 73 2008 1679 1682
37. A. Nudelman, Y. Bechor, E. Falb, B. Fischer, B.A. Wexler, and A. Nudelman Acetyl chloride-methanol as a convenient reagent for: a) quantitative formation of amine hydrochlorides b) carboxylate ester formation c) mild removal of N-t-Boc-protective group Synth. Commun. 28 1998 471 474